<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49FFE305-71E4-41B1-87AC-8E58220B1F28"><gtr:id>49FFE305-71E4-41B1-87AC-8E58220B1F28</gtr:id><gtr:name>Novartis Institutes for Biomedical Research (NIBR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CE97FC1C-8B83-431B-8DE7-749A3C4A5F95"><gtr:id>CE97FC1C-8B83-431B-8DE7-749A3C4A5F95</gtr:id><gtr:firstName>Bart</gtr:firstName><gtr:surname>Vanhaesebroeck</gtr:surname><gtr:orcidId>0000-0002-7074-3673</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/221E0A73-CD1F-41E3-B678-262222B2B39A"><gtr:id>221E0A73-CD1F-41E3-B678-262222B2B39A</gtr:id><gtr:firstName>Sharon</gtr:firstName><gtr:otherNames>A.</gtr:otherNames><gtr:surname>Tooze</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700755"><gtr:id>00B1BDBA-304D-40A2-BACC-BAB1275C601C</gtr:id><gtr:title>Roles of PI 3-kinase isoforms in autophagy and endosomal membrane dynamics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700755</gtr:grantReference><gtr:abstractText>One of the most fundamental component parts of the human body is a structure termed a cell. Every cell is surrounded by a membrane of fat which maintains its identity separate from the surrounding environment. Furthermore, every cell is subdivided into more compartments by itself containing discrete and unique membrane-bound structures termed organelles. In order for a cell to function it must be able to perform a number of roles including communication with the extracellular milieu, the regulated transfer of material between organelles and the recycling of aged material within the cell itself. Defects in any of these functions can lead to abberations which ultimately cause the cell to malfunction and lead to cancer, the unregulated growth of cells. 
Our laboratory works on catalysts within the cell termed PI3Ks. PI3Ks are able to specifically manipulate the composition of the cellular membranes. These manipulations are critical to ensure fidelity of the transfer of material between organelles and between the external environment and organelles. 
The importance of these PI3Ks in maintaining normal cellular functions is highlighted by the fact that they are compromised in a high percentage of tumors. Consequently it is obvious that if we wish to tackle the causes of cancer and try to cure patients suffering from cancer it is vital that we know how PI3Ks function in whole organisms. The main problem with this avenue of enquiry however is that there are numerous flavors of PI3K within cells and each performs a distinct role within the cell. To this end our laboratory generate mice models where the activity of discrete PI3Ks are specifically ablated, both at the level of cells and the whole organism. By this methodology we are able to assign specific roles to each PI3K and in combination with drug companies design small molecule inhibitors targeted towards each PI3K. These small molecule inhibitors are then tested in directed experiments to see whether they will be of any therapeutic use in tackling cancer and other health issues arising from defective PI3K signalling.</gtr:abstractText><gtr:technicalSummary>PI 3-kinases (PI3Ks) are signalling enzymes that play key roles in cell physiology. Deregulated PI3K signalling has been implicated in cancer, inflammation and diabetes, and PI3Ks are being pursued as new therapeutic targets by the pharmaceutical industry. Mammals have 8 distinct isoforms of PI3K, several of which (p110a, p110b and vps34p) have been implicated in the regulation of membrane dynamics with respect to autophagy and endosomal dynamics.The current proposal aims to investigate how both autophagy and endosomal dynamics are regulated by members of the PI3K family.
Autophagy (Self Eating) is a cellular phenomenon whereby cytosolic components are sequestered within a double membrane structure and irreversibly degradated inside lysosomes. Autophagy has recently been linked to a wide range of human pathologies, including cancer, neurodegeneration and vacuolar myopathies but the mechanistic details of how autophagy is regulated remain largely obscure. It is believed that one of the class I PI3Ks directs an inhibitory signal to autophagic processes, the isoform is currently unknown but we have preliminary evidence that it is p110a. Conversely vps34p, a class III PI3K, sends a stimulatory signal to boost levels of autophagy within the cell. The nature of these signals may reflect a lipid kinase event in the production of PI3P, however it is possible that vps34p plays a scaffolding role in maintaining the stoichiometry of a protein complex vital in the regulation of autophagy. 
Proper control of the flux of membranes through endosomes is important as misregulation can lead to prooncogenic signaling from internalized receptors that are destined for the lysosomes in order to ablate their progrowth signals. A failure in lysosomal delivery will prolong the oncogenic signaling and thus predispose the cell to becoming cancerous. Membrane trafficking within endosomes is in part controlled by the localized production of PI3P. The source of the PI3P is a disputed area and be made by vps34p or by the sequential action of class I PI3Ks and 5- and 4-phosphatases. 
This proposal will make use of newly created PI3K gene-targeted mice and cell-based models to resolve fundamental issues concerning the roles of PI3K isoforms in autophagy and endosomal membrane trafficking and endocytosis. Increased understanding of these phenonomena is not only important from a fundamental science point of view but may also enable modulation of these cellular phenomena in a therapeutic manner through the application of small molecule inhibitors directed against distinct PI3K isoforms.</gtr:technicalSummary><gtr:fund><gtr:end>2011-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>369237</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis Institutes for BioMedical Research (NIBR)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with Novartis Research Institution - Boston USA</gtr:description><gtr:id>41E0AD7C-F637-42B6-83BF-EE487AF57538</gtr:id><gtr:impact>A manuscript describing the results of these studies is currently under review</gtr:impact><gtr:outcomeId>58aa07f7e86a58.58666003-1</gtr:outcomeId><gtr:partnerContribution>Novartis provided a small molecule inhibitor against the vps34 Pi 3-kinase under MTA,</gtr:partnerContribution><gtr:piContribution>We have received a small molecule inhibitor from Novartis under MTA, and tested this compound to validate our genetic data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research UK London Research Institute (LRI)</gtr:department><gtr:description>Electron Microscopy - Lucy Collinson and Sharon Tooze - London</gtr:description><gtr:id>8DBEB977-DAB6-4C31-92FA-6EC7997E7C7F</gtr:id><gtr:impact>This work is anticipated to at least one high profile publication.

Multidisciplinary: biology, embryology, microscopy</gtr:impact><gtr:outcomeId>Nzy72k5HVrn-1</gtr:outcomeId><gtr:partnerContribution>Expertise in Electron Microscopy</gtr:partnerContribution><gtr:piContribution>Provision of biological samples - co-formulation of scientific questions to be addressed.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Science Week Events and Talks</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B296AED0-134B-4CFD-AD61-BC4C266C3E35</gtr:id><gtr:impact>Discussion on working in Science - animals in research

various interactions with people interested in science</gtr:impact><gtr:outcomeId>5464e9e597d567.60247612</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lab Tours and School Visits</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2C33A219-A2A0-4563-8FB6-3116A4A74BF4</gtr:id><gtr:impact>- over 200 lay people have attended tours in our laboratory
- PI presented the work to over 500 schoolchildren over the period 2007-2012
- PI has hosted placements of pupils in the lab


- PI is asked for return visits every year + additional invitations to talk
- stimulates children to consider careers in science and research</gtr:impact><gtr:outcomeId>hKyAoUQtEs8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Programme Grant (BB/I007806/1and BB/I007806/2)</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>6D1D2D7D-7596-4C12-9F6F-B31B0E53201B</gtr:id><gtr:outcomeId>5464f4132d4510.01936134</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Programme Grant - Bart Vanhaesebroeck</gtr:description><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>DB9C8798-7007-4394-90B1-D5F0C637191D</gtr:id><gtr:outcomeId>prj8WcHCvMw0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mice in which the vps34 PI 3-kinase is inactivated in a constitutive or conditional manner. This mouse line can be used in pre-clinical models of disease, such as cancer and diabetes. We may ultimately licence these mice to pharma, as we have done for our other PI3K mutant mice.</gtr:description><gtr:id>11F92643-DB1B-43B6-9907-C984CFA75738</gtr:id><gtr:impact>- Extensive collaborations in UK, US and France.
- Allowed other people to apply for grants using these materials
- successful bid to BBSRC for programme grant follow-up funding</gtr:impact><gtr:outcomeId>YxCxYv2nEtG</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>vps34 mutant mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0967C250-7A52-4BD2-A484-0F5D00BC4D39</gtr:id><gtr:title>Vps34 PI 3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/520c870110ebf202e9aff789538e642b"><gtr:id>520c870110ebf202e9aff789538e642b</gtr:id><gtr:otherNames>Bilanges B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a35b0eb5e8ad0.31280682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B41B175-CAA0-44F2-A8D3-57CBA8F2668F</gtr:id><gtr:title>A dual role for the class III PI3K, Vps34, in platelet production and thrombus growth.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6003e08ded43e3309926e4584114292"><gtr:id>a6003e08ded43e3309926e4584114292</gtr:id><gtr:otherNames>Valet C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a35d0a9649e11.48089574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B54B39E6-B8B7-40EE-89B5-3E6ED1FA9ADF</gtr:id><gtr:title>Long-term p110a PI3K inactivation exerts a beneficial effect on metabolism.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/feaeb1b73f83de9d7c3eae4d3152e7ac"><gtr:id>feaeb1b73f83de9d7c3eae4d3152e7ac</gtr:id><gtr:otherNames>Foukas LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>doi_55f984984687bc5f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CAC5D1E-EAB4-4C1B-B697-951E2953DBE5</gtr:id><gtr:title>A new tool to dissect the function of p70 S6 kinase.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/520c870110ebf202e9aff789538e642b"><gtr:id>520c870110ebf202e9aff789538e642b</gtr:id><gtr:otherNames>Bilanges B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>LniXh4LMv9b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAB1C6B3-CF3D-48BD-9284-8E79D9CD5099</gtr:id><gtr:title>Essential role of class II PI3K-C2a in platelet membrane morphology.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6003e08ded43e3309926e4584114292"><gtr:id>a6003e08ded43e3309926e4584114292</gtr:id><gtr:otherNames>Valet C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5675e74356b82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB7456BF-43E2-4E28-B527-ED192ACF0C62</gtr:id><gtr:title>Regulation of p110delta PI 3-kinase gene expression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfc033a1f35778d43c7e98214534c4a7"><gtr:id>dfc033a1f35778d43c7e98214534c4a7</gtr:id><gtr:otherNames>Kok K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54623894c67562.89896977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78F00C57-54D0-4A3D-8A71-8820F7BAA610</gtr:id><gtr:title>The emerging mechanisms of isoform-specific PI3K signalling.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Molecular cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e8ef3720a283f60669bc6948866244e"><gtr:id>6e8ef3720a283f60669bc6948866244e</gtr:id><gtr:otherNames>Vanhaesebroeck B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-0072</gtr:issn><gtr:outcomeId>XQ5Bdt4E1P4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F857E1CE-9BF2-4B9C-AAC5-BB99CA007B51</gtr:id><gtr:title>Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4c1e0bfb643645f3be9f9b905e054fb"><gtr:id>c4c1e0bfb643645f3be9f9b905e054fb</gtr:id><gtr:otherNames>Papakonstanti EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>54623894527330.10108305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A19E5A3-35E1-4E8F-9338-B7CCD994D83A</gtr:id><gtr:title>Killing two kinase families with one stone.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/520c870110ebf202e9aff789538e642b"><gtr:id>520c870110ebf202e9aff789538e642b</gtr:id><gtr:otherNames>Bilanges B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>LLU3mTtKcz8</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700755</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>